Key Highlights

● Glaukos posted record third-quarter net sales of $211.0 million against $168 million expected.

● Epioxa generated $53 million in revenue, more than triple the $17 million consensus.

● Management raised 2026 sales guidance to $775 million to $785 million.

● The company offered an initial 2027 sales view of about $1 billion.

Glaukos (NYSE:GKOS) blew past Revenue estimates with a record quarter, swung to a profit and raised its full-year sales outlook, making it one of Thursday's most spectacular gainers.

A record quarter

Glaukos, the California eye-care company known for tiny stents used to treat glaucoma, delivered the kind of quarter that rewrites expectations. Third-quarter net sales hit a record $211.0 million, far above the $168 million analysts had expected, according to one report. Sales soared from a year earlier, and the company swung to a profit.

The stock rocketed on Thursday, October 29, trading at $241.01 at 3:40pm according to market data and ranking among the biggest gainers in the S&P MidCap 400. Sources tracking the move through the day differed on its exact size, but all described a surge, with the stock building on its gains from mid-morning into the afternoon.

Epioxa steals the show

The standout line in the report was Epioxa. The product generated $53 million in revenue in the quarter, more than three times the $17 million consensus. A beat of that scale on a newer product is exactly what growth investors hope to see, because it suggests adoption is happening faster than modelled and that the revenue base can keep expanding for years.

A record Top Line combined with a return to profitability marks a shift from a company investing for the future to one that is starting to show the payoff.

Guidance lifted, and a peek at 2027

Management raised its 2026 sales guidance to a range of $775 million to $785 million. It also offered an initial view of 2027 sales of about $1 billion, a milestone figure that gives investors a clear target. For a company of Glaukos' size, crossing the billion-dollar mark would be a significant moment.

Health care leads the market

Glaukos' surge came on a day when health care was the best-performing sector in the S&P 500. Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK) rallied on their own beats, and investors rotated into health care, financials and real estate, according to market data. One report highlighted Glaukos alongside several other health care names that posted outsized gains, including Teladoc (NYSE:TDOC) and Bausch Health (NYSE:BHC).

The broader indexes were split. The S&P 500 slipped 23.59 points to 7,720.39 as Alphabet (NASDAQ:GOOGL)'s historic plunge weighed on technology, while the Nasdaq Composite fell 365.13 points to 26,184.72. Small and mid caps fared far better, with the Russell 2000 up 28.71 points to 2,859.22. "Money is rotating within the market rather than leaving it," said one market strategist, a line that captured why a medical device company could leap while Big Tech sank.

What made the move so large

Big beats on revenue are common in Earnings season; beats of this size are not. When a company's sales come in tens of millions of dollars above estimates and a key product triples forecasts, analysts typically have to revise their models sharply upward, and the stock reprices to match. Thursday's surge reflected that kind of reset.

What to watch

The new 2026 range of $775 million to $785 million implies a strong fourth quarter, and investors will be looking for Glaukos to deliver against it. The early 2027 view of about $1 billion will be scrutinised as analysts update their forecasts.

Epioxa's trajectory is the critical variable. Whether its launch momentum holds will determine how quickly Glaukos can grow into its new valuation. Broader sentiment toward health care, which led Thursday's rotation, will also matter if investors swing back toward technology.